06182nam a22008535i 45000010014000000030009000140050017000230060019000400070015000590080041000740200018001150240031001330350021001640350022001850400033002070410008002400440015002480500025002630720023002880820018003112450167003292640054004962640011005503000043005613360026006043370026006303380036006563470024006925051061007165060104017775201121018815380049030025460016030515880112030676500035031796500053032146500042032676500032033096530019033416530027033606530011033876530009033986530009034076530019034166530016034356530019034516530031034706530021035016530011035226530025035336530018035587000081035767000084036577000085037417000090038267000084039167000089040007000096040897000084041857000078042697000085043477000079044327000084045117000084045957000083046797000084047627000082048467730120049288560042050488560049050908560080051399120085052199120024053049781487529055DE-B159720211129102213.0m|||||o||d||||||||cr || ||||||||211129t20212021onc    fo  d z      eng d  a97814875290557 a10.3138/97814875290552doi  a(DE-B1597)596745  a(OCoLC)1240721288  aDE-B1597bengcDE-B1597erda0 aeng  aonccCA-ON 4aRA401.A1bT73 2021eb 7aMED0000002bisacsh04a362.17/8222300aTransparency, Power, and Influence in the Pharmaceutical Industry :bPolicy Gain or Confidence Game? /ced. by Matthew Herder, Janice Graham, Katherine Fierlbeck. 1aToronto : bUniversity of Toronto Press, c[2021] 4c©2021  a1 online resource (304 p.) :b1 figure  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda00tFrontmatter -- tContents -- t1 Introduction -- t2 Transparency, Pharmaceuticals, and the Problem of Policy Change -- t3 Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? -- t4 The FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency -- t5 Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader -- t6 The Limits of Transparency and the Role of Essential Medicines -- t7 Speak No Secrets: (Non)transparency in Health Canada’s Communications about Pharmaceutical Regulation -- t8 The Political Economy of Influence: Ghost-Management in the Pharmaceutical Sector -- t9 Data Transparency and Rare Disease: Privacy versus Public Interest? -- t10 The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency -- t11 The Road Forward: How Researchers Can Sustain an Ethical and Transparent Health System -- t12 Conclusion -- tContributors -- tIndex0 arestricted accessuhttp://purl.org/coar/access_right/c_16ecfonline access with authorization2star  aThere is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet regulators have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between pharmaceutical industry and government regulators. Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products.  aMode of access: Internet via World Wide Web.  aIn English.0 aDescription based on online resource; title from PDF title page (publisher's Web site, viewed 29. Nov 2021) 0aPharmaceutical policyzCanada. 0aPharmaceutical policyzEuropean Union countries. 0aPharmaceutical policyzUnited States. 7aMEDICAL / General.2bisacsh  aclinical data.  aconflicts of interest.  adrugs.  aema.  afda.  ahealth Canada.  ahealth law.  ahealth policy.  apharmaceutical regulation.  apharmaceuticals.  apower.  ascientific evidence.  atransparency.1 aBanzi, Rita, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aDanyliuk, Anna, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aDavis, Courtney, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aFierlbeck, Katherine, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aFierlbeck, Katherine, eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aGagnon, Marc-André, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aGhimire, Kanksha Mahadevia, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aGraham, Janice, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aGraham, Janice, eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aHerder, Matthew, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aHerder, Matthew, eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aJefferson, Tom, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aLemmens, Trudo, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aLexchin, Joel, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aMulinari, Shai, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb1 aPersaud, Nav, econtributor.4ctb4https://id.loc.gov/vocabulary/relators/ctb08iTitle is part of eBook package:dDe GruytertUniversity of Toronto Press Complete eBook-Package 2021z978311073922040uhttps://doi.org/10.3138/978148752905540uhttps://www.degruyter.com/isbn/9781487529055423Coveruhttps://www.degruyter.com/document/cover/isbn/9781487529055/original  a978-3-11-073922-0  University of Toronto Press Complete eBook-Package 2021b2021  aGBV-deGruyter-alles